Activity Content
Atrial fibrillation (AF) is a major public health problem in the United States. In 2001, approximately 2.3 million Americans had AF, and, with the graying of America, that number is expected to increase to an estimated 12–16 million by the year 2050. In addition, AF is a costly disorder. The estimated annual direct health care cost for a patient with AF is $15,553 compared with $3,204 for a patient without AF. Hospitalization is the major cost driver in treating patients with AF, accounting for about 62% of its total cost. AF causes substantial morbidity and mortality and adversely affects quality of life. It is associated with new or worsening heart failure and stasis of blood in the atria, which may lead to thromboembolic events, primarily in the form of a stroke.
This activity will address the pharmacologic management of atrial fibrillation, focusing on three primary therapeutic goals: prevention of thromboembolism (primarily stroke), sinus rhythm control, and heart rate control. The current standard of care, as well as the efficacy and safety of established and investigational drug therapies for rhythm and rate control and prevention of thromboembolism, will be discussed. Pharmacoeconomic considerations in treating atrial fibrillation will be reviewed, and the role of managed care pharmacists in the management of AF through policy and process strategies, population management strategies, and case management will be discussed. Case studies will illustrate the application of concepts to specific patient and managed care scenarios.